Alzheimer's disease: implications of the updated diagnostic and research criteria.
E. Reiman,G. Mckhann,M. Albert,R. Sperling,R. Petersen,D. Blacker
DOI: https://doi.org/10.4088/JCP.10087co1c
2011-09-01
Abstract:A lzheimer’s disease (AD) is the most common form of disabling cognitive impairment in older people. AD dementia has been estimated to affect an estimated 5.4 million Americans, and by 2050, it is projected to affect about 13.5 million older US adults.1,2 According to the World Alzheimer’s Report,3 the number of afflicted people and the associated costs of AD are projected to skyrocket around the world due to the growing number of people living to older ages. In 1984, Work Groups for the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA, more commonly known as the Alzheimer’s Association) developed the original clinical diagnostic criteria for AD.4 At that time, AD was considered a discrete clinicopathological entity, requiring evidence of dementia and likely or confirmed evidence of moderate-to-severe AD neuropathology.5 Progress in research during the past 27 years has led investigators to reconceptualize AD as a progressive sequence of biological changes, some of which can be measured using brain imaging and other biomarkers, which roughly correspond to preclinical and increasingly severe clinical stages of the disorder. Among several findings, researchers have shown that many patients with mild cognitive impairment (MCI) have biological evidence of AD and are at increased risk for progression to AD dementia6; identified pathophysiologic evidence of AD years before the onset of symptoms in cognitively normal people at increased risk for MCI and dementia due to AD; suggested that AD-modifying treatments might have the most profound effect if started before the onset of symptoms, when extensive neuropathology may already be evident; and characterized other disease processes that may contribute to disabling cognitive impairment (eg, Lewy bodies and vascular disease) in patients with or without pathophysiologic evidence of AD. To begin the process of revising the diagnostic criteria, the National Institute on Aging (NIA) and the Alzheimer’s Association held advisory meetings in 2009, during which attendees agreed that 3 separate work groups be formed in relationship to the dementia, MCI, and preclinical stages of AD.7 The work groups were asked to review scientific progress, propose diagnostic criteria for dementia due to AD and dementia due to MCI, and begin to establish research criteria for preclinical stages of AD. Five of the work group members participated in this Commentary discussion: Guy M. McKhann, MD, chaired the work group on AD dementia, as well as the work group that proposed the original NINCDS/ADRDA diagnostic criteria in 1984. Marilyn S. Albert, PhD, chaired the work group on MCI due to AD. Ronald C. Petersen, MD, PhD (a pioneer in MCI research), served as a member of the MCI due to AD work group. Reisa A. Sperling, MD, chaired the work group on preclinical AD, and Eric M. Reiman, MD, served as a member; both of these investigators have been actively involved in the use of brain imaging techniques in the preclinical stages of AD. The recommendations established by each work group were presented at the 2010 International Conference on Alzheimer’s Disease and were posted on the Alzheimer’s Association’s Web site for public review. After submitted comments were incorporated by the work groups as appropriate, a subcommittee reviewed the semi-final publications and made additional revisions, In April 2011, the National Institute on Aging (NIA) and the Alzheimer’s Association Work Groups proposed updated criteria for the diagnosis of Alzheimer’s disease (AD), including dementia due to AD and mild cognitive impairment due to AD, as well as research criteria to begin defining the preclinical stages of AD. On April 25, Eric M. Reiman, MD, assembled several leading experts to discuss the updated diagnostic and research criteria for AD, including the conceptualization of AD as a sequence of biological changes that roughly correspond to the preclinical and increasingly severe clinical stages of the disorder, how the criteria might be related to developing the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria and other suggested diagnostic criteria, and the potential implications and impact of those criteria on clinical practice. Their discussion appears here.